您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > (+)-Matrine(Vegard)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
(+)-Matrine(Vegard)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
(+)-Matrine(Vegard)图片
CAS NO:519-02-8
规格:≥98%
包装与价格:
包装价格(元)
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)248.36
FormulaC15H24N2O
CAS No.519-02-8
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 49 mg/mL (197.3 mM)
Water: 11 mg/mL (44.29 mM)
Ethanol: 49 mg/mL (197.3 mM)
Solubility (In vivo)

Chemical Name: (41S,7aS,13aR,13bR)-dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one

InChi Key: ZSBXGIUJOOQZMP-JLNYLFASSA-N

InChi Code: InChI=1S/C15H24N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15-/m0/s1

SMILES Code: O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@H]([C@@H]34)CN12

Synonyms

Vegard; α-Matrine; Matridin-15-one; NSC 146051; NSC146051; Matrine; NSC-146051;

实验参考方法
In Vitro

In vitro activity: Matrine((+)-Matrine) is an alkaloid found in plants from the Sophora family, which has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor agonist. Matrine significantly inhibites the growth of human non-small cell lung cancer A549 and hepatoma SMMC-7721 cells and induces apoptosis by strongly reducing the viability and the ratio of Bcl-2/Bax protein in A549 cells. matrine may stimulate the descending dynorphinergic neuron, resulting in the stimulation of kappa-opioid receptors (KORs) in the spinal cord, and this phenomenon in turn produces the antinociception in mice.

In VivoOral administration of matrine (200, 100 and 50 mg/kg) significantly attenuated isoproterenol-induced cardiac necrosis and left ventricular dysfunction. high dose of matrine significantly reduced the mortality rate of mice with LPS administration. Treatment with matrine improved LPS-induced lung histopathologic changes, alleviated pulmonary edema and lung vascular leak, inhibited MPO and MDA activity,and reduced the production of inflammatory mediators including TNF-α, IL-6 and HMGB1
Animal modelMouse
Formulation & Dosage200, 100 and 50 mg/kg
References

Biol Pharm Bull. 2005 May;28(5):845-8; Cytotechnology. 2009 Apr;59(3):191-200.